Floatz logo

Valspodar

Childhood Myelodysplastic Syndromes

National Cancer Institute (NCI)protein_peptidePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Childhood Myelodysplastic Syndromes cohort.

Asset / SponsorPhaseRating
Fludarabine
Children's Oncology Group
Phase 3BBB
Cytosin-Arabinosid
Children's Oncology Group
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BB
Busulphan
Fred Hutchinson Cancer Center
Phase 3BB
ETOPOSIDE
City of Hope Medical Center
Phase 3BB

View all 34 →

Same molecule, other indications

Valspodar is also rated in:

acute erythroid leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
acute megakaryoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
acute myeloid leukemia with minimal differentiationDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →